ClinicalTrials.gg
RecruitingNCT07722546GRAVITATEUpdated Nov 12, 2026

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

A Phase 2 interventional study of Felzartamab and Placebo in Graves' Disease, sponsored by Biogen. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 12, 20268 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Graves Disease with a site in United States — 16 open to participants now, 18 under way, 3 of them phase 3. Graves Disease · United States.

Planned enrollment
20th of 33
60 · median 76
Started
2026
with 9 others
Phase 2
10 of 43
5 open now
Primary completion
2028-01
later than 10 of 17 live
Registered
41st of 43
by date
Lead sponsor
1 of 43
Biogen

Among the 43 studies in Graves Disease with a site in United States, this one is the 20th largest by planned enrollment of the 33 interventional ones that give a count, is one of 10 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 10 of the 17 other live ones, and was the 41st registered.

Graves Disease

162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.

Browse Graves Disease studies →

Open to participants now

16 of the 43 studies in Graves Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Graves Disease with a site in United States, or all of them as a file.
02

Study summary

In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal antibodies, called thyroid-stimulating hormone receptor antibodies (TRAb), that attack the thyroid gland. This causes the thyroid to become too active and produce too much hormone, a condition called hyperthyroidism.

Participants with GD are often treated with anti-thyroid drugs, or ATDs, which are medicines that help bring thyroid hormone levels back to normal. Felzartamab is designed to target certain immune cells that produce the abnormal TRAb antibodies.

The main goal of the study is to learn whether felzartamab can help bring thyroid hormone levels back to normal and allow participants to stop taking ATDs. Participants will receive either felzartamab or placebo during the study. A placebo looks like the study drug but contains no real medicine.

The main question that researchers want to answer is:

  • How many participants have normal thyroid levels without receiving any ATD medicine at Week 24?

Researchers will also learn more about the safety of felzartamab and how the body processes the drug.

The study will be done as follows:

  • Participants will be screened to check if they can join the study.
  • This is a double-blind study, which means neither the participants, study doctor, or site staff will know if participants are receiving felzartamab or a placebo.
  • Participants will be placed into 1 of 3 groups. Two groups will receive felzartamab while the other receives placebo.
  • Participants will receive felzartamab or placebo as intravenous (IV) infusions, which are slow injections into a vein using a needle. The Treatment Period will last 20 weeks.
  • During the Treatment Period, the study doctor may gradually lower the dose of the ATD if a participant's thyroid levels become normal.
  • Afterwards, participants will enter a follow-up period which will last 12 weeks.
  • In total, participants will have 22 study visits. Participants will stay in the study for about 9 months (up to 36 weeks).
Read the detailed description

The primary objective of the study is to evaluate the efficacy of felzartamab compared to placebo in participants with Grave's disease (GD). The secondary objectives of the study are to evaluate the safety, efficacy and pharmacokinetics (PK) of felzartamab in participants with GD.

03

Conditions studied

  • Graves' Disease

Keywords

  • Hyperthyroidism
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have active disease and are thyroid-stimulating hormone receptor antibodies (TRAb) positive, defined as:

    • Free thyroxine (FT4) and free triiodothyronine (FT3), within the reference range,
    • suppressed thyroid-stimulating hormone (TSH)
    • TRAb levels > (ULN)
  • Participants must be receiving stable dose of anti-thyroid drugs (ATD) for at least 12 weeks prior to randomization.
  • Must agree to refrain from blood product donation from Screening through end of study. If a participant terminates early from the study, they must refrain from blood product donation for 90 days following the last dose of study drug.

Key Exclusion Criteria:

  • History of thyroidectomy or radioactive iodine therapy.
  • ATD dose change within 12 weeks prior to Day1, or anticipated need for dose adjustment prior to randomization (except for protocol-defined safety management).
  • Active, moderate-to-severe, or sight threatening thyroid eye disease (TED) (as assessed by the clinical activity score [CAS]), or requirement for imminent or ongoing TED-directed therapy (e.g., systemic , biologic therapy, orbital radiation, surgery).
  • Any history of within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.
  • History of hyperthyroidism not caused by GD (e.g. toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis) and/or history or presence of thyroid storm.
  • Type 1 diabetes and type 2 diabetes mellitus with (HbA1c) > 8%.
  • Known or suspected history of to felzartamab or its .
  • Use of therapy within 5 half-lives/12 weeks of Screening.
  • Co-existing diseases that require systemic immunosuppressants (e.g., cyclosporine, methotrexate, biologics, monoclonals).
  • Prior use of an anti-Neonatal Fragment Crystallizable Receptor (FcRn) therapy or intravenous immunoglobulin (IVIg) within 6 months of the last dose prior to Screening.
  • Any condition that requires chronic use of high-dose steroids.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive multiple IV doses of placebo.

    Drug: Placebo

  • Experimental
    Felzartamab or Placebo

    Participants will receive multiple IV doses of felzartamab or placebo.

    Drug: Felzartamab · Drug: Placebo

  • Experimental
    Felzartamab

    Participants will receive multiple IV doses of felzartamab.

    Drug: Felzartamab

Interventions

  • Administered IV

    Also known as: BIIB148, MOR202, MOR03087, TJ202

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who are Euthyroid and off Anti-Thyroid Drugs (ATD) at Week 24

    Time frame: At Week 24

Secondary outcomes

  1. Percentage of Participants who Have Down-Titrated to ≤ 50% of Their Baseline ATD and are Euthyroid at Week 12 and Week 24

    Time frame: At Weeks 12 and 24

  2. Percentage of Participants who are Euthyroid at Week 12 and Week 24

    Time frame: At Weeks 12 and 24

  3. Change From Baseline in Free Triiodothyronine (FT3)

    Time frame: Baseline up to Week 32

  4. Change From Baseline in Free Thyroxine (FT4)

    Time frame: Baseline up to Week 32

  5. Change From Baseline in Thyroid-Stimulating Hormone (TSH)

    Time frame: Baseline up to Week 32

  6. Change From Baseline in ATD Levels

    Time frame: Up to Week 24

  7. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)

    Time frame: From first dose of study drug up to end of study follow-up (Up to Week 32)

  8. Felzartamab Serum Concentrations Over Time

    Time frame: Predose and at multiple timepoints postdose up to Week 24

  9. Number of Participants with Anti-drug Antibodies (ADAs) Against Felzartamab

    Time frame: Baseline up to Week 24

07

Study locations

15 of 15 sites recruiting
  • Sun City Clinical Research
    Glendale, Arizona 85304, United States
    Recruiting
    • · Contact623-253-9777
    • Rohit Dwivedi · Principal investigator
  • AME Clinical Research
    Los Angeles, California 92647, United States
    Recruiting
    • · Contact714-375-5970
    • Chris Tsimerekis · Principal investigator
  • San Jose Clinical Trials
    San Jose, California 95128, United States
    Recruiting
    • · Contact408-443-3542
    • Richard Cherlin · Principal investigator
  • DM Clinical Research
    Doral, Florida 33166, United States
    Recruiting
    • · Contact786-789-1036
    • Noreen Shaaban · Principal investigator
  • LAMK Research and Health
    Hialeah, Florida 33012, United States
    Recruiting
    • · Contact805-330-1261
    • Lysette Iglesias · Principal investigator
  • Floridian Clinical Research - Clinitiative
    Miami, Florida 33016, United States
    Recruiting
    • · Contact305-330-9977
    • Marco Fiore · Principal investigator
  • Bioluminux Clinical Research
    Naperville, Illinois 60540, United States
    Recruiting
    • · Contact331-401-5117
    • Adeshola Ezeokoli · Principal investigator
  • Patient First Clinical Trials (PFCTrials)
    Lutherville, Maryland 21093, United States
    Recruiting
    • · Contact410-832-3968
    • Greg Tampus · Principal investigator
  • Bioluminux Clinical Research
    Hamilton, New Jersey 08690, United States
    Recruiting
    • · Contact609-613-6859
    • Matthew Adasofunjo · Principal investigator
  • Asheville Clinical Research
    Asheville, North Carolina 28803, United States
    Recruiting
    • · Contact828-579-2273
    • Lauren Bernstein · Principal investigator
  • M3 Wake Research - Dallas
    Dallas, Texas 75246, United States
    Recruiting
    • · Contact469-297-3074
    • Carlos Arauz-Pacheco · Principal investigator
  • Gulf Coast Clinical Research
    Houston, Texas 77070, United States
    Recruiting
    • · Contact281-640-2940
    • Anjani Pandya · Principal investigator
  • Accurate Clinical Research, Inc
    Humble, Texas 77346, United States
    Recruiting
    • · Contact281-760-3930
    • Brian Chou · Principal investigator
  • Patient First Clinical Trials (PFCTrials)
    Richmond, Virginia 23229, United States
    Recruiting
    • · Contact804-613-5079
    • Ritu Madan · Principal investigator
  • Solace Clinical Research - Puerto Rico
    Bayamón, 00959, Puerto Rico
    Recruiting
    • · Contact787-425-4881
    • Carmen Pizarro · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jan 2028, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
Jul 30, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added
Show 8 added (8 United States)
  • Patient First Clinical Trials (PFCTrials) · Lutherville, United States
  • Bioluminux Clinical Research · Hamilton, United States
  • Patient First Clinical Trials (PFCTrials) · Richmond, United States
  • Gulf Coast Clinical Research · Houston, United States
  • Accurate Clinical Research, Inc · Humble, United States
  • San Jose Clinical Trials · San Jose, United States
  • Bioluminux Clinical Research · Naperville, United States
  • LAMK Research and Health · Hialeah, United States
across 6 updates, Oct 2, 2026 – Nov 12, 2026
Show all 6 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • LAMK Research and Health · Hialeah, United States
    + 1 other change: verification date
  2. Oct 28, 2026
    2 sites added
    Show 2 added (2 United States)
    • San Jose Clinical Trials · San Jose, United States
    • Bioluminux Clinical Research · Naperville, United States
  3. Oct 22, 2026
    1 site added
    Show site
    • Accurate Clinical Research, Inc · Humble, United States
  4. Oct 14, 2026
    1 site added
    Show site
    • Gulf Coast Clinical Research · Houston, United States
  5. Oct 7, 2026
    2 sites added
    Show 2 added (2 United States)
    • Bioluminux Clinical Research · Hamilton, United States
    • Patient First Clinical Trials (PFCTrials) · Richmond, United States
  6. Oct 2, 2026
    1 site added
    Show site
    • Patient First Clinical Trials (PFCTrials) · Lutherville, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07722546
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Jul 30, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

US Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
866-633-4636
Global Biogen Clinical Trial Center
Contact
clinicaltrials@biogen.com
Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion